Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA issues complete response letter for Opdivo

Nov. 30, 2015

New CD137/HER2 bispecific Anticalin-based protein shows promising antitumoral activity

Nov. 30, 2015

New bispecific antibody prodrug shows preclinical efficacy

Nov. 27, 2015

Adaptimmune initiates phase I/II study of NY-ESO TCR therapy in NSCLC

Nov. 27, 2015

Aduro's CRS-207 receives EMA orphan drug designation for malignant pleural mesothelioma

Nov. 27, 2015

Combination of pembrolizumab and chemotherapy feasible in metastatic cancer

Nov. 26, 2015

Anti-PDPN MAb ChLpMab-7 shows potential as anticancer therapy

Nov. 26, 2015

FDA clears University of Minnesota to conduct phase I/II trial of OXS-1550

Nov. 26, 2015

FDA approves Opdivo for previously untreated BRAF V600 wild-type advanced melanoma

Nov. 25, 2015

FDA approves Portrazza for metastatic squamous NSCLC

Nov. 25, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.